Stockreport

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics, Inc.  (TVTX) 
PDF New PDUFA target action date is April 13, 2026Commercial launch preparations continue in anticipation of potential approval SAN DIEGO--(BUSINESS WIRE)--Travere Therap [Read more]